己酮可可碱疗法在口腔黏膜下纤维化治疗中的应用
Pentoxifylline therapy in the management of oral submucous fibrosis.
作者信息
Mehrotra Ravi, Singh H P, Gupta S C, Singh M, Jain S
机构信息
Departments of Pathology, MLN Medical College and SRN Hospital, Allahabad, India.
出版信息
Asian Pac J Cancer Prev. 2011;12(4):971-4.
OBJECTIVES
Oral submucous fibrosis is a common premalignant condition in the Indian subcontinent and is caused by chewing areca nut and other irritants in various forms. Its medical treatment is not yet fully standardized. In this study we compared the efficacy of Pentoxifylline as compared to placebo.
MATERIALS AND METHODS
75 patients suffering from oral submucous fibrosis were randomly divided into two groups A and B. Group A patients received placebo, while Group B patients received 400 mg. Pentoxifylline for a period of 7 months. Treatment outcome was evaluated on the basis of improvement in symptom and sign scores. Student's t test was applied for comparing the results.
RESULTS
The improvement in total (i.e. symptoms + sign) score was 25% in group A and 49.15% in group B. This difference was found to be statistically significant. (p < 0.05)
CONCLUSION
Treatment regimen of group B was more effective. No significant side effects were seen. A follow up study is required to assess long term outcome of this therapy.
目的
口腔黏膜下纤维化是印度次大陆一种常见的癌前病变，由咀嚼槟榔及其他各种形式的刺激物引起。其医学治疗尚未完全标准化。在本研究中，我们比较了己酮可可碱与安慰剂的疗效。
材料与方法
75例口腔黏膜下纤维化患者被随机分为A组和B组。A组患者接受安慰剂，而B组患者接受400毫克己酮可可碱，为期7个月。根据症状和体征评分的改善情况评估治疗结果。采用学生t检验比较结果。
结果
A组总（即症状+体征）评分改善率为25%，B组为49.15%。发现这种差异具有统计学意义（p<0.05）。
结论
B组治疗方案更有效。未观察到明显副作用。需要进行随访研究以评估该疗法的长期效果。
Zotero 插件